Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05429346 · ClinicalTrials.gov registry record

Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity

A clinical trial of Racial Disparities and Maternal Morbidity, sponsored by Kaiser Permanente.

Recruiting
Registry status
339,000
Enrollment target
1
Study location

NCT05429346: Recruiting study of Racial Disparities and Maternal Morbidity, sponsored by Kaiser Permanente.

NCT05429346 is a study of Racial Disparities and Maternal Morbidity that is actively recruiting participants, run by Kaiser Permanente. The registered enrollment target is 339,000 participants, above the 70-participant average among 5 other Racial Disparities trials with a reported enrollment target (484186% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05429346, a study of Racial Disparities and Maternal Morbidity, is actively recruiting participants, sponsored by Kaiser Permanente.

RECRUITING
Registry status
339,000 participants
Enrollment target
1
Study location

Study Summary

Severe Maternal Morbidity (SMM) has been associated with maternal mortality, fetal risk, and long-term maternal risk. African American (AA) women are at consistently higher risk than White women. However, factors contributing to these racial disparities are largely unknown and commonly known factors have not been able to explain them, so strategies to reduce them are absent. CDC reports that the rate of GHSV infection is 4 times higher in AA than White women. Studies have shown that pregnant women with genital herpes simplex virus (GHSV) infection are at higher risk of SMM and that treating women with GHSV using existing anti-herpes medications could reduce SMM risk. To address the question of racial disparities in SMM and examine the comparative effectiveness of treating women with GHSV infection to reduce the risk of SMM, the investigators are conducting a large cohort study with a two-stage design, combining an EMR-based cohort (Stage I) with a sub-cohort interview (Stage II) to examine the impact of confounders not available from EMR data. Based on status of GHSV and treatment, 4 cohorts of women will be established: (1) those with GHSV infection receiving treatment early in pregnancy; (2) those with GHSV infection receiving treatment later in pregnancy; (3) those with GHSV infection untreated during pregnancy; and (4) those without GHSV. Given that racial disparities in SMM present serious challenges, the study will provide much needed data to address the effectiveness of treating GHSV on reducing racial disparities in SMM.

Study Locations (1)

California

  • Division of Research, Kaiser Permanente Northern California - Oakland

Trial Details

FieldValue
Enrollment Target 339,000 participants
Start Date 2023-01-08
Est. Completion 2026-04-30
Kaiser Permanente

294 total trials

What NCT05429346 shows while recruiting

NCT05429346 is an observational study that tracks outcomes without assigning an intervention. Its 339,000 participants enrollment target places it among the larger protocols in the corpus, above the 70-participant average among 5 other Racial Disparities trials with a reported enrollment target (484186% higher).

The record links to 3 conditions, with Racial Disparities appearing as the primary indexed condition, and to 0 interventions.

NCT05429346 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05429346 about?

NCT05429346 is a clinical study titled "Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity". Severe Maternal Morbidity (SMM) has been associated with maternal mortality, fetal risk, and long-term maternal risk. African American (AA) women are at consistently higher risk than White women. However, factors contributing to these racial disparities are largely unknown and commonly known factors...

What is the current status of trial NCT05429346?

This trial is currently recruiting. The enrollment target is 339,000 participants. The study started on 2023-01-08. Estimated completion is 2026-04-30.

What conditions does trial NCT05429346 study?

This clinical trial studies the following conditions: Racial Disparities, Maternal Morbidity, Genital Herpes Simplex.

Who is sponsoring clinical trial NCT05429346?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05429346 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Racial Disparities

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05668637 · 318,542 participants

    Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

  • NCT05365048 · 301,201 participants · NA

    Provider Recommendation and HPV Vaccination

  • NCT02280733 · 300,000 participants

    A Real-World Registry of Chronic Wounds and Ulcers

  • NCT06694181 · 300,000 participants

    Safe and Explainable AI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05429346, the US trial registry maintained by the National Library of Medicine. NCT05429346 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.